Ongericimab

DB18949InvestigationalProtein Based Therapies

Ongericimab is under investigation in clinical trial NCT05325203 (A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (Hefh).).

Mechanism: Pharmacologically active on Proprotein convertase subtilisin/kexin type 9
Curator reviewed
Also known as: Immunoglobulin g4-kappa, anti-(homo sapienspcsk9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, narc1, narc-1, proprotein convertase 9, pc9)), humanized monoclonal antibody · Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain), disulfide with human monoclonal js002 .kappa.-chain, dimer
Code names: JS-002

Resolves to

Compound

UNIIX126G5DZ36CAS2145096-91-7

Targets

Q8NBP7PCSK9

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ongericimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account